Fig. 6

Immune infiltration status and drug sensitivity analysis in low-risk and high-risk groups of gastric cancer patients. (A) Tumor purity. (B) ESTIMATE score. (C) Stromal Score. (D) Immune phenotype score (IPS). (E) Proportions of 23 types of cells in low-risk and high-risk subgroups of patients. (F) Correlation between immune cell infiltration and prognostic genes. (G) Dasatinib. (H) Erlotinib. (I) Imatinib. (J) Paclitaxel. (K) Rapamycin. (L) Saracatinib. (M) Sorafenib. (N) Sunitinib.